NTRK1 and systemic mastocytosis: Years later, midostaurin was shown to be a potent inhibitor of the FLT3 tyrosine kinase and to have activity against mutant forms of KIT receptor tyrosine kinase which drive advanced systemic mastocytosis (SM).